Praxis Precision Medicines, Inc. PRAX
346.21 USD +8.62 (+2.55%)
At closeNov 11, 2026, 7:23 PM EST
342.94 -3.27 -0.94%
After hours · Nov 11, 7:23 PM ET
334.17 Day range 351.64
160.11 52-week range 392.70
- YTD
- +17.46%
- 1 year
- +88.61%
News
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly -…
benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.- benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $188 to $189.
benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Lowers Price Target to $343 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and lowers the price target from $362 to $343.- benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $826 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $826 price target.
globenewswire.com Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
globenewswire.com Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
globenewswire.com Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
benzinga.com JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 JP Morgan analyst Tessa Romero initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight rating and announces Price Target of $700.
benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
benzinga.com BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826 BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $810 to $826.
benzinga.com Praxis Precision Medicine Q2 2026 Earnings Call Transcript Praxis Precision Medicine (NASDAQ:PRAX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access…
globenewswire.com Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
defenseworld.net Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM) Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will…- benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
- benzinga.com Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.
defenseworld.net Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat…
seekingalpha.com Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA…
globenewswire.com Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
defenseworld.net Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from Brokerages Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company,…- benzinga.com Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575 Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
defenseworld.net Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High – What’s Next? Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at…
defenseworld.net 9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and…
zacks.com 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
seekingalpha.com Praxis: Commercial Launch Could Smash Expectations (Video) Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial…
benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.- benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
marketbeat.com Praxis Precision Medicines Q2 Earnings Call Highlights Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and…
benzinga.com Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582 Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.
benzinga.com Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.- benzinga.com Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over…
globenewswire.com Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
globenewswire.com Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $810 price target.
defenseworld.net Bank of New York Mellon Corp Boosts Stock Position in Praxis Precision Medicines, Inc. $PRAX Bank of New York Mellon Corp raised its holdings in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 11.7% during the first quarter, according to the company in its most recent Form 13F filing with…
defenseworld.net Fifth Third Bancorp Acquires New Holdings in Praxis Precision Medicines, Inc. $PRAX Fifth Third Bancorp bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the first quarter, according to the company in its most recent 13F filing with the Securities and…- benzinga.com Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447 Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
- benzinga.com Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential Tremor Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population…
- benzinga.com Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS)…
benzinga.com Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.- benzinga.com Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575 Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $537 to $575.
benzinga.com Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction data in SCN2A-DEE.- benzinga.com Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug…
- benzinga.com RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449 RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announces Price Target of $449.
- benzinga.com Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650 Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $750 to $650.
- benzinga.com Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616 Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.
- benzinga.com Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374 Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $420 to $374.